AVXL
Anavex Life Sciences Corp. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares +30.0% ·
flujo de acciones +4.6% ·
nuevas posiciones netas +20.0%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 31.52M | $81.72M | +7 | −8 |
| Q1 2026 | 83 | +4 | 34.46M | $105.82M | +13 | −9 |
| Q4 2025 | 79 | +2 | 31.53M | $112.26M | +2 | — |
| Q3 2025 | 14 | 0 | 20.35M | $181.11M | — | — |
| Q2 2025 | 11 | -2 | 18.83M | $173.63M | — | −2 |
| Q1 2025 | 10 | -1 | 6.83M | $58.56M | — | −1 |
| Q4 2024 | 11 | +3 | 6.21M | $66.68M | +3 | — |
| Q3 2024 | 7 | -2 | 3.52M | $20.02M | — | −2 |
| Q2 2024 | 9 | — | 3.99M | $16.85M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 2.41M | — | $25.90M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (pasivo) | 1.87M | -0.4% | $20.14M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (pasivo) | 1.87M | -0.4% | $20.14M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 776.90K | -6.5% | $8.34M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 240.91K | +843.8% | $2.59M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 213.20K | -12.6% | $2.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 207.78K | -39.1% | $2.23M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 158.67K | Nuevo | $1.70M | 0.0% | New | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 158.67K | Nuevo | $1.70M | 0.0% | New | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 141.12K | Nuevo | $1.52M | 0.0% | New | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 141.12K | Nuevo | $1.52M | 0.0% | New | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 105.13K | Nuevo | $1.13M | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 48.31K | -64.6% | $518,903 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 48.31K | -64.6% | $518,903 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 48.31K | -64.6% | $518,903 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 29.20K | -53.7% | $314,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Wellington Management | $1.70M | 0.0% |
| Wellington Management | $1.70M | 0.0% |
| Marshall Wace | $1.52M | 0.0% |
| Marshall Wace | $1.52M | 0.0% |
| D. E. Shaw & Co. | $1.13M | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 39.00K acciones, $119 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.